San Antonio BC Symposium ‘19! It’s here!

TailorX “results” will continue to be published for years to come. While the initial, long awaited results were presented a year ago, subsequent results continue....here is one that was published two months ago in JAMA....

https://www.ptcommunity.com/wire/new-tailorx-data-published-today-jama-oncology-add-strong-evidence-base-reinforcing-

REDWOOD CITY, Calif., Sept. 30, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which reinforce the unique value of the Oncotype DX Breast Recurrence Score® test to guide the use of adjuvant chemotherapy for women with hormone receptor-positive (HR+), HER2-negative, early-stage breast cancer and identify those patients who derive a significant benefit from treatment. The findings, published today in JAMA Oncology1 and presented at the ESMO 2019 Congress2, are consistent with results from the B20 trial3 and show that, in patients with high Recurrence Score results (26-100) treated with endocrine therapy plus chemotherapy, outcomes were better compared to what would be expected with endocrine therapy alone. The analysis also provides details on the outcomes of different chemotherapy regimens for the minority of patients who benefit from chemotherapy.......

furthermore....for those patients with 1-3 positive nodes, with respect to the OncotypeDX test, the trial is “closed”, so hopefully in 2021 we should start seeing those results....

https://www.swog.org/clinical-trials/s1007

i haven’t had the time to look at an outline of the presentations, but I am sure there should, as always, be some outstanding info to chew on!

https://www.mysanantonio.com/news/texas/article/New-drugs-show-rare-promise-against-advanced-14898697.php

https://www.oncnet.com/news/adding-capecitabine-standard-adjuvant-chemo-improves-dfs-patients-tnbc

https://www.targetedonc.com/conference/sabcs-2019/preventative-breast-cancer-effect-maintained-with-anastrozole-in-longterm-followup-data

https://www.prnewswire.com/news-releases/new-evidence-from-large-studies-highlights-value-of-oncotype-dx-breast-recurrence-score-to-guide-chemotherapy-treatment-in-young-patients-with-node-negative-or-node-positive-early-stage-breast-cancer-300973702.html

https://www.cancertherapyadvisor.com/home/news/conference-coverage/san-antonio-breast-cancer-symposium-sabcs/sabcs-2019/breast-cancer-maintenance-durvalumab-shows-activity-certain-subgroups/

https://www.cancertherapyadvisor.com/home/news/conference-coverage/san-antonio-breast-cancer-symposium-sabcs/sabcs-2019/breast-cancer-paclitaxel-trastuzumab-offers-same-survival-outcomes/

https://www.ajmc.com/conferences/sabcs-2019/age-associated-to-benefit-derived-from-chemotherapy-for-women-with-luminal-breast-cancer-mindact-trial-finds-

https://www.curetoday.com/conferences/sabcs-2019/awareness-for-men-with-breast-cancer-is-starting-to-take-hold-at-major-conferences

https://www.onclive.com/conference-coverage/sabcs-2019

there are some great studies being reported...

https://www.eurekalert.org/pub_releases/2019-12/no-bt121319.php